Wang Xiao-Ke, Yang Xin, Yao Tong-Han, Tao Peng-Xian, Jia Guan-Jun, Sun De-Xian, Yi Lin, Gu Yuan-Hui
The First School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, China.
Department of General Surgery, Gansu Provincial Hospital, Lanzhou 730000, Gansu Province, China.
World J Gastrointest Oncol. 2024 Jul 15;16(7):2915-2924. doi: 10.4251/wjgo.v16.i7.2915.
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal-derived tumors of the GI tract. They can occur throughout the GI tract, and the survival time of some patients can be improved by first-line targeted therapy with imatinib. However, there are some limitations with imatinib treatment. Immunotherapy for GIST has attracted much attention in recent years, and as one of the most abundant cells in the GIST microenvironment, M2 macrophages play an important role in disease progression. They have unique anti-inflammatory and pro-tumorigenic effects and are one target for immunotherapy. This review summarizes the connection between different factors and the programmed death receptor-1/programmed death ligand-1 pathway and M2 macrophages to reactivate or enhance anti-tumor immunity and improve imatinib efficacy, and to provide new ideas for GIST immunotherapy.
胃肠道间质瘤（GIST）是胃肠道最常见的间充质来源肿瘤。它们可发生于整个胃肠道，部分患者的生存时间可通过伊马替尼一线靶向治疗得到改善。然而，伊马替尼治疗存在一些局限性。近年来，GIST的免疫治疗备受关注，作为GIST微环境中最丰富的细胞之一，M2巨噬细胞在疾病进展中起重要作用。它们具有独特的抗炎和促肿瘤作用，是免疫治疗的一个靶点。本综述总结了不同因素与程序性死亡受体-1/程序性死亡配体-1通路及M2巨噬细胞之间的联系，以重新激活或增强抗肿瘤免疫力并提高伊马替尼疗效，为GIST免疫治疗提供新思路。
